Eradication of helicobacter Pylori in triple therapy regimen supplemented by green tea extract compared with routine triple therapy regimen

A clinical trial on the effects of green tea extract plus triple therapy regimen compared with triple therapy regimen on eradication of helicobacter Pylori in in patients diagnosed with helicobacter Pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061317756N18

Enrollment

Registered

2017-07-10

Start date

2016-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention Group: The intervention group received the routine triple therapy regimen plus green tea extract pill (450 mg twice daily) for two weeks. Four weeks after completion of in

Treatment - Drugs

Intervention Group: The intervention group received the routine triple therapy regimen plus green tea extract pill (450 mg twice daily) for two weeks. Four weeks after completion of intervention, urea

Control Group: The control group only received the routine triple therapy regimen for two weeks. Four weeks after completion of intervention, urease breath test was performed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Positive result of urease breath test (UBT) and/or rapid urease test for diagnosis of helicobacter pylori; having indications for Helicobacter pylori treatment; willingness to cooperate in the study; lack of green tea consumption by the patient prior to the study onset; no history of macrolide. Exclusion criteria: Previous treatment for helicobacter pylori; consumption of proton pump inhibitors from a month before the test, or blockers of H2 receptor 24 hours before the test, or antibiotics and bismuth from two weeks before the test; pregnancy; malignancy; gastrectomy; severe liver disease or any other severe disease within the past two years; any sensitivity to penicillin or other substances used in the medication regimen; incomplete consumption of the drugs for any reason.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Eradication of helicobacter pylori. Timepoint: Four weeks after intervention was completed. Method of measurement: Urease breath test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaila Omidvar

Birjand University of Medical Sciences

Roozgar@bums.ac.ir+98 56 3239 5680

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026